Citations 2
Is minimally invasive glaucoma surgery killing trabeculectomies?
Loon, Seng Chee, White, Andrew , Ang, Bryan C H
Current Opinion in Ophthalmology | November 15, 2024 | Volume: 36 | Issue: 2 | Pages: 146-151
Purpose of review The introduction of minimally invasive glaucoma surgery (MIGS) has changed the surgical landscape of glaucoma surgery. For more than four decades, the most commonly performed glaucoma surgery around the world has been the trabeculectomy. This article examines whether trabeculectomy is still the predominant procedure in glaucoma today, in the context of rapidly emerging MIGS devices and procedures. Recent findings There is a growing trend of mild to moderate glaucoma cases undergoing MIGS procedures instead of trabeculectomy. Glaucoma drainage device implantation may also have taken away a significant share of the filtering surgery performed for more severe glaucoma. In addition, the availability and economics of implants has an influence on the prevalence of trabeculectomy. Summary Currently, trabeculectomy surgery is still the most common glaucoma surgery performed around the world. However, the proportion of glaucoma surgeries undergoing MIGS is increasing rapidly.
Adding an extension piece to the end of the purge side arm of the Impella device can prevent the incidence of the cassette breaking and decrease the Impella device failure rate: Impact of practice change on patient outcome
SATASHIA, PARTHKUMAR , White, Andrew D. , Isha, Shahin , Hanson, Abby , Jenkins, Anna , Blasavage, Jessica, Matos, Nikki , Tomlinson, Amanda, Zhang, Stephanie , Quiñones, Quintin J., Waldron, Nathan H. , Kiley, Sean , Chaudhury, Sanjay, Shapiro, Anna B, Sanghavi, Devang , White, Andrew , Quinones, Quintin, Waldron, Nathan, Guru, Pramod K , Sanghavi, Devang K., Jenkins, Anna S , Shahin, Isha , White, Andrew, Bhattacharyya, Anirban , Guru, Pramod , Franco, Pablo Moreno
Perfusion | December 7, 2023 | Volume: 39 | Issue: 8 | Pages: 1757-1760
Background: Impella 5.5® with Smart Assist is a minimally invasive Left Ventricular Assist Devices (LVAD) approved by the Food and Drug Administration (FDA) for treating ongoing cardiogenic shock for up to 14 days. The Impella® intends to reduce ventricular workload and provide the circulatory support necessary for myocardial recovery. Research Question: Compared to standard practice, does adding an extension piece to the purge tube side arm of the Impella® Device decrease the incidence of device failure and positively impact the health outcome of adult patients receiving Impella® support? Study Design and Methods: A retrospective chart review of ICU patients was done at a tertiary care center from August 2018 to August 2022 to assess the differences in patient outcomes related to Impella® Device utilization before and after the implementation of the extension piece to the purge tube sidearm. Among patients reviewed, a total of 20 were included in our review, with seven not having the purge tube side arm extension added, while 13 patients had the extension. Results: The two study groups had no significant difference in patient health outcomes. Additionally, there were no instances of device failure requiring explanation without the extension tubing. However, there were no cases of the purge cassette cracking with the addition of the extension tubing. Conclusion: The addition of extension tubing to the purge cassette of the Impella® Device did not impact patient health outcomes or the incidence of device failure. There was a complete reduction in the incidence of the purge cassette cracking, which could reduce the potential for infection or device failure over a long period of mechanical support. There is a need for long-term prospective studies to confirm the results.